- Class: Tyrosine kinase inhibitor (TKI)
- Mechanism: Selective inhibitor of VEGFR-1, -2, and -3 → blocks angiogenesis
- Indication:
- Advanced renal cell carcinoma (RCC) (as monotherapy or in combination with immunotherapy, e.g., pembrolizumab or avelumab)
- Dosing:
- 5 mg orally BID; can be titrated based on tolerance
- Key Toxicities:
- Hypertension (very common)
- Diarrhea, fatigue, hand-foot syndrome
- Proteinuria, thromboembolic events
- Monitoring:
- BP, urine protein, liver function, TSH
- Food: Take without regard to food
Synonyms
Axitinib, Inlyta